Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial
Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.
Benzinga ·